Novo breaks with Hims – is the stock plunge just the beginning or already an opportunity?

The telemedicine provider Hims & Hers Health is under significant pressure following the surprising break with Danish pharmaceutical giant Novo Nordisk. The stock plummeted more than 30% on Monday – the largest single-day loss in the company’s history. The trigger was Novo's announcement to terminate its cooperation with Hims and consider legal action for the allegedly illegal manufacture and marketing of copies of the weight loss drug Wegovy (active ingredient: Semaglutide). But is this really the end of Hims’ GLP-1 business? Probably...